Amplification and Overexpression of the IGF2 Regulator PLAG1 in Hepatoblastoma

Genes Chromosomes and Cancer

Volumn 39, Issue 2, 2004, Pages 126-137

  Zatkova, Andrea ^a   Rouillard, Jean Marie ^b   Hartmann, Wolfgang ^c   Lamb, Barbara J ^b   Kuick, Rork ^b   Eckart, Markus ^a   Von Schweinitz, Dietrich ^d   Koch, Arend ^c   Fonatsch, Christa ^a   Pietsch, Torsten ^c   Hanash, Sam M ^b   Wimmer, Katharina ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF BONN   (Germany)

^d UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CONTIG; GENOMIC DNA; RNA; SOMATOMEDIN B;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHILDHOOD CANCER; CHROMOSOME 8Q; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; EXPRESSED SEQUENCE TAG; FEMALE; FETUS; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENE SEQUENCE; HEPATOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NEWBORN; NUCLEOTIDE SEQUENCE; PLAG1 GENE; PRIORITY JOURNAL; REGULATOR GENE; RESTRICTION LANDMARK GENOMIC SCANNING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION; VIRTUAL GENOME SCAN;

ADULT; CELL LINE, TUMOR; CHILD; CHROMOSOMES, HUMAN, PAIR 8; COMPUTATIONAL BIOLOGY; DNA, NEOPLASM; DNA-BINDING PROTEINS; FETUS; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOBLASTOMA; HUMANS; INFANT, NEWBORN; INSULIN-LIKE GROWTH FACTOR II; LIVER; LIVER NEOPLASMS; PROMOTER REGIONS (GENETICS); TRANS-ACTIVATION (GENETICS); TRANSFECTION;

EID: 9144234767     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/gcc.10307     Document Type: Article

References (46)

1. Albrecht S, Waha A, Koch A, Kraus JA, Goodyer CG, Pietsch T. 1996. Variable imprinting of H19 and IGF2 in fetal cerebellum and medulloblastoma. J Neuropathol Exp Neurol 55:1270-1276.
2. Almeida A, Zhu XX, Vogt N, Tyagi R, Muleris M, Dutrillaux AM, Dutrillaux B, Ross D, Malfoy B, Hanash S. 1998. GAC1, a new member of the leucine-rich repeat superfamily on chromosome band 1q32.1, is amplified and overexpressed in malignant gliomas. Oncogene 16:2997-3002.
3. Anneren G, Nordlinder H, Hedborg F. 1992. Chromosome aberrations in an alpha-fetoprotein-producing hepatoblastoma. Genes Chromosomes Cancer 4:99-100.
4. Asakawa J, Kuick R, Neel JV, Kodaira M, Satoh C, Hanash SM. 1995. Quantitative and qualitative genetic variation in two-dimensional DNA gels of human lymphocytoid cell lines. Electrophoresis 16:241-252.
5. Astrom AK, Voz ML, Kas K, Roijer E, Wedell B, Mandahl N, Van de Ven W, Mark J, Stenman G. 1999. Conserved mechanism of PLAG1 activation in salivary gland tumors with and without chromosome 8q12 abnormalities: identification of SII as a new fusion partner gene. Cancer Res 59:918-923.
6. Dai Z, Zhu WG, Morrison CD, Brena RM, Smiraglia DJ, Raval A, Wu YZ, Rush LJ, Ross P, Molina JR, Otterson GA, Plass C. 2003. A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenes. Hum Mol Genet 12:791-801.
7. Fletcher JA, Kozakewich HP, Pavelka K, Grier HE, Shamberger RC, Korf B, Morton CC. 1991. Consistent cytogenetic aberrations in hepatoblastoma: a common pathway of genetic alterations in embryonal liver and skeletal muscle malignancies? Genes Chromosomes Cancer 3:37-43.
8. Ginzinger DG, Godfrey TE, Nigro J, Moore DH, 2nd, Suzuki S, Pallavicini MG, Gray JW, Jensen RH. 2000. Measurement of DNA copy number at microsatellite loci using quantitative PCR analysis. Cancer Res 60:5405-5409.
9. Gisselsson D, Hibbard MK, Dal Cin P, Sciot R, Hsi BL, Kozakewich HP, Fletcher JA. 2001. PLAG1 alterations in lipoblastoma: involvement in varied mesenchymal cell types and evidence for alternative oncogenic mechanisms. Am J Pathol 159:955-962.
10. Gray SG, Kytola S, Matsunaga T, Larsson C, Ekstrom TJ. 2000. Comparative genomic hybridization reveals population-based genetic alterations in hepatoblastomas. Br J Cancer 83:1020-1025.
11. Hartmann W, Waha A, Koch A, Goodyer CG, Albrecht S, von Schweinitz D, Pietsch T. 2000. p57(KIP2) is not mutated in hepatoblastoma but shows increased transcriptional activity in a comparative analysis of the three imprinted genes p57(KIP2), IGF2, and H19. Am J Pathol 157:1393-1403.
12. Hartmann W, Waha A, Koch A, Albrecht S, Gray SG, Ekstrom TJ, von Schweinitz D, Pietsch T. 2001. Promoter-specific transcription of the IGF2 gene: a novel rapid, non-radioactive and highly sensitive protocol for mRNA analysis. Virchows Arch 439:803-807.
13. Hatada I, Hayashizaki Y, Hirotsune S, Komatsubara H, Mukai T. 1991. A genomic scanning method for higher organisms using restriction sites as landmarks. Proc Natl Acad Sci USA 88:9523-9527.
14. Hensen K, Van Valckenborgh IC, Kas K, Van de Ven WJ, Voz ML. 2002. The tumorigenic diversity of the three PLAG family members is associated with different DNA binding capacities. Cancer Res 62:1510-1517.
15. Hibbard MK, Kozakewich HP, Dal Cin P, Sciot R, Tan X, Xiao S, Fletcher JA. 2000. PLAG1 fusion oncogenes in lipoblastoma. Cancer Res 60:4869-4872.
16. Holthuizen PE, Cleutjens CB, Veenstra GJ, van der Lee FM, Koonen-Reemst AM, Sussenbach JS. 1993. Differential expression of the human, mouse and rat IGF-II genes. Regul Pept 48:77-89.
17. Hu J, Wills M, Baker BA, Perlman EJ. 2000. Comparative genomic hybridization analysis of hepatoblastomas. Genes Chromosomes Cancer 27:196-201.
18. Hughes SJ, Glover TW, Zhu XX, Kuick R, Thoraval D, Orringer MB, Beer DG, Hanash S. 1998. A novel amplicon at 8p22-23 results in overexpression of cathepsin B in esophageal adenocarcinoma. Proc Natl Acad Sci USA 95:12410-12415.
19. Kas K, Voz ML, Roijer E, Astrom AK, Meyen E, Stenman G, Van de Ven WJ. 1997. Promoter swapping between the genes for a novel zinc finger protein and beta-catenin in pleiomorphic adenomas with t(3;8)(p21;q12) translocations. Nat Genet 15:170-174.
20. Knuutila S, Bjorkqvist AM, Autio K, Tarkkanen M, Wolf M, Monni O, Szymanska J, Larramendy ML, Tapper J, Pere H, El-Rifai W, Hemmer S, Wasenius VM, Vidgren V, Zhu Y. 1998. DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. Am J Pathol 152:1107-1123.
21. Larsen F, Gundersen G, Lopez R, Prydz H. 1992. CpG islands as gene markers in the human genome. Genomics 13:1095-1107.
22. Li X, Adam G, Cui H, Sandstedt B, Ohlsson R, Ekstrom TJ. 1995. Expression, promoter usage and parental imprinting status of insulin-like growth factor II (IGF2) in human hepatoblastoma: uncoupling of IGF2 and H19 imprinting. Oncogene 11:221-229.
23. Lin L, Aggarwal S, Glover TW, Orringer MB, Hanash S, Beer DG. 2000. A minimal critical region of the 8p22-23 amplicon in esophageal adenocarcinomas defined using sequence tagged site-amplification mapping and quantitative polymerase chain reaction includes the GATA-4 gene. Cancer Res 60:1341-1347.
24. Lindsay S, Bird AP. 1987. Use of restriction enzymes to detect potential gene sequences in mammalian DNA. Nature 327:336-338.
25. Mascarello JT, Jones MC, Kadota RP, Krous HF. 1990. Hepatoblastoma characterized by trisomy 20 and double minutes, Cancer Genet Cytogenet 47:243-247.
26. Misra P, Qi C, Yu S, Shah SH, Cao WQ, Rao MS, Thimmapaya B, Zhu Y, Reddy JK. 2002. Interaction of PIMT with transcriptional coactivators CBP, p300 and PBP: differential role in transcriptional regulation. J Biol Chem 277:20011-20029.
27. Nigro JM, Takahashi MA, Ginzinger DG, Law M, Passe S, Jenkins RB, Aldape K. 2001. Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. Am J Pathol 158: 1253-1262.
28. Pietsch T, Fonatsch C, Albrecht S, Maschek H, Wolf HK, von Schweinitz D. 1996. Characterization of the continuous cell line HepT1 derived from a human hepatoblastoma. Lab Invest 74: 809-818.
29. Rainier S, Dobry CJ, Feinberg AP. 1995. Loss of imprinting in hepatoblastoma. Cancer Res 55:1836-1838.
30. Rickman DS, Tyagi R, Zhu XX, Bobek MP, Song S, Blaivas M, Misek DE, Israel MA, Kurnit DM, Ross DA, Kish PE, Hanash SM. 2001. The gene for the axonal cell adhesion molecule TAX-1 is amplified and aberrantly expressed in malignant gliomas. Cancer Res 61:2162-2168.
31. Rodriguez E, Reuter VE, Mies C, Bosl GJ, Chaganti RS. 1991. Abnormalities of 2q: a common genetic link between rhabdomyosarcoma and hepatoblastoma? Genes Chromosomes Cancer 3:122-127.
32. Rouillard JM, Erson AE, Kuick R, Asakawa J, Wimmer K, Muleris M, Petty EM, Hanash S. 2001. Virtual genome scan: a tool for restriction landmark-based scanning of the human genome. Genome Res 11:1453-1459.
33. Sainati L, Leszl A, Stella M, Montaldi A, Perilongo G, Rugge M, Bolcato S, Iolascon A, Basso G. 1998. Cytogenetic analysis of hepatoblastoma: hypothesis of cytogenetic evolution in such tumors and results of a multicentric study. Cancer Genet Cytogenet 104:39-44.
34. Silverman L, Sudol M, Resh MD. 1993. Members of the src family of nonreceptor tyrosine kinases share a common mechanism for membrane binding. Cell Growth Differ 4:475-482.
35. Surace C, Leszl A, Perilongo G, Rocchi M, Basso G, Sainati L. 2002. Fluorescent in situ hybridization (FISH) reveals frequent and recurrent numerical and structural abnormalities in hepatoblastoma with no informative karyotype. Med Pediatr Oncol 39:536-539.
36. Toretsky JA, Helman LJ. 1996. Involvement of IGF-II in human cancer. J Endocrinol 149:367-372.
37. van Dijk MA, van Schaik FM, Bootsma HJ, Holthuizen P, Sussenbach JS. 1991. Initial characterization of the four promoters of the human insulin-like growth factor II gene. Mol Cell Endocrinol 81:81-94.
38. Voz ML, Astrom AK, Kas K, Mark J, Stenman G, Van de Ven WJ. 1998. The recurrent translocation t(5;8)(p13;q12) in pleomorphic adenomas results in upregulation of PLAG1 gene expression under control of the LIFR promoter. Oncogene 16:1409-1416.
39. Voz ML, Agten NS, Van de Ven WJ, Kas K. 2000. PLAG1, the main translocation target in pleomorphic adenoma of the salivary glands, is a positive regulator of IGF-II. Cancer Res 60:106-113.
40. Weber RG, Pietsch T, von Schweinitz D, Lichter P. 2000. Characterization of genomic alterations in hepatoblastomas. A role for gains on chromosomes 8q and 20 as predictors of poor outcome. Am J Pathol 157:571-578.
41. Weinberg AG, Finegold MJ. 1983. Primary hepatic tumors of childhood. Hum Pathol 14:512-537.
42. Wimmer K, Zhu XX, Lamb BJ, Kuick R, Ambros PF, Kovar H, Thoraval D, Motyka S, Alberts JR, Hanash SM. 1999. Co-amplification of a novel gene, NAG, with the N-myc gene in neuroblastoma. Oncogene 18:233-238.
43. Wimmer K, Zhu XX, Rouillard JM, Ambros PF, Lamb BJ, Kuick R, Eckart M, Weinhausl A, Fonatsch C, Hanash SM. 2002. Combined restriction landmark genomic scanning and virtual genome scans identify a novel human homeobox gene, ALX3, that is hypermethylated in neuroblastoma. Genes Chromosomes Cancer 33:285-294.
44. Yi TL, Bolen JB, Ihle JN. 1991. Hematopoietic cells express two forms of lyn kinase differing by 21 amino acids in the amino terminus. Mol Cell Biol 11:2391-2398.
45. Zhu Y, Kan L, Qi C, Kanwar YS, Yeldandi AV, Rao MS, Reddy JK. 2000. Isolation and characterization of peroxisome proliferator-activated receptor (PPAR) interacting protein (PRIP) as a coactivator for PPAR. J Biol Chem 275:13510-13516.
46. Zhu Y, Qi C, Cao WQ, Yeldandi AV, Rao MS, Reddy JK. 2001. Cloning and characterization of PIMT, a protein with a methyltransferase domain, which interacts with and enhances nuclear receptor coactivator PRIP function. Proc Natl Acad Sci USA 98:10380-10385.